Moreover, a recent study by Cheng et al. suggests that UCP2 can enhance the anti-tumor responses of CD8+ T cells in an interferon regulatory factor 5-dependent manner (Cheng et al., 2019). This evidence concerns the gene IRF5 and neoplasm.